Searched for
RYALTRIS NASAL SPRAY
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analysts
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%
- Glenmark’s nasal spray Ryaltris gets China’s NMPA nod for allergic rhinitis; to be commercialised by Grand PharmaRyaltris is a fixed-dose combination of olopatadine, an antihistamine and mometasone furoate, a corticosteroid to treat the symptoms of all...10 Nov, 2025, 11.36 PM IST
- Glenmark Pharma shares in focus as Q1 profit slumps 86% YoYGlenmark Pharma reported an 86% YoY drop in Q1FY26 net profit to Rs 46.9 crore, even as revenue stayed flat at Rs 3,264 crore. EBITDA slipp...18 Aug, 2025, 09.01 AM IST
- US prospects, new drugs make Glenmark look betterGlenmark's marketing portfolio as of December 2024 had 201 generic products authorised for distribution in the US. The company has 51 appli...09 Apr, 2025, 06.20 AM IST
- No revision, Glenmark Pharma sticking to full-year guidance: VS ManiVS Mani, CFO of Glenmark Pharma, discusses the company's strong performance in FY25 with an average of Rs 1,100 crore per quarter. Challeng...17 Feb, 2025, 02.15 PM IST
- Glenmark arm recalls products in US for manufacturing issuesGlenmark Pharmaceuticals is recalling 45,504 bottles of Ryaltris Nasal Spray and 11,568 tubes of Ciclopirox Gel in the US due to manufactur...13 Oct, 2024, 12.21 PM IST
- Glenmark bets on respiratory drug, licensing deals to improve businessGlenmark had gross debt of ₹3,765 crore as of June 30, 2022. The company over the years accumulated debt to fund its innovation-led R&D and...16 Sep, 2022, 12.14 PM IST
- Glenmark's partner Hikma launches specialty drug Ryaltris in USRyaltris is the only fixed-dose combination of olopatadine hydrochloride and mometasone furoate approved by the USFDA for the treatment of ...30 Aug, 2022, 07.21 PM IST
- Glenmark Pharma inks exclusive licensing agreement with Lotus InternationalGlenmark will receive an upfront payment as well as regulatory and sales-based milestone payments from Lotus, it added.20 Jan, 2022, 10.24 AM IST
- Glenmark gets USFDA nod for nasal spray to treat seasonal allergic rhinitisGlenmark Pharmaceuticals on Friday said its subsidiary has received approval from the US health regulator to market Ryaltris, a nasal spray...14 Jan, 2022, 10.15 AM IST
- Glenmark gets marketing approval for Ryaltris in 13 EU, UK countriesSales of the nasal spray continue to progress well in Australia, South Africa, Ukraine and Uzbekistan, it said adding the company has also ...30 Sep, 2021, 11.33 AM IST
- Glenmark Pharma launches nasal spray Ryaltris in IndiaGlenmark being one of the leaders in respiratory segment, has been the first to launch the branded generic version at an affordable cost fo...03 May, 2021, 11.25 AM IST
- Glenmark Pharma to launch its nasal spray Ryaltris in EUThe drug relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and wate...26 Apr, 2021, 01.22 PM IST
- Glenmark arm gets Russian health ministry nod for nasal spray RyaltrisIn Russia, allergic rhinitis affects 10-20 per cent of the population on average, with certain regions having a higher prevalence rate of 1...22 Feb, 2021, 11.52 AM IST
- Glenmark inks pact with Menarini Group to commercialise nasal spray in EuropeGlenmark Specialty, a Switzerland-based unit of the company, has entered into an exclusive licensing agreement with the Menarini Group for ...23 Dec, 2020, 11.59 AM IST
- Market Movers: RITES falls as OFS sails, Axis Bank gains; buy signals in 25 stocksThe BSE flagship shed 143 points to 39,745 while Nifty dipped 45 points to 11,633.27 Feb, 2020, 05.10 PM IST
- Glenmark gets approval from Australian regulator to commercialise RyaltrisGlenmark is entitled to receive commercial milestone payments from Seqirus.20 Dec, 2019, 03.44 PM IST
- Glenmark Pharma says USFDA has issued CRL for RyaltrisThe CRL cites deficiencies in the Drug Master File pertaining to one of the active pharmaceutical ingredients and in manufacturing faciliti...22 Jun, 2019, 03.49 PM IST
Load More
